

UC San Diego

UC San Diego Previously Published Works

Title

Brief Report: Frailty and HIV Disease Severity Synergistically Increase Risk of HIV-Associated Neurocognitive Disorders.

Permalink

<https://escholarship.org/uc/item/7g74n5hk>

Journal

Journal of acquired immune deficiency syndromes (1999), 84(5)

ISSN

1525-4135

Authors

Sun-Suslow, Ni
Paolillo, Emily W
Morgan, Erin E
et al.

Publication Date

2020-08-01

DOI

10.1097/qai.0000000000002391

Peer reviewed

Frailty and HIV disease severity synergistically increase risk of HIV-associated Neurocognitive Disorders

Ni Sun-Suslow, Ph.D.¹, Emily W. Paolillo, M.S.^{1,2}, Erin E. Morgan, Ph.D.¹, Scott Letendre, M.D.^{1,3}, Jennifer Iudicello, Ph.D.¹, and David J. Moore, Ph.D.¹

¹ Department of Psychiatry, University of California San Diego, San Diego, California 92093, USA

² San Diego State University/University of California San Diego Joint Doctoral Program in Clinical Psychology, San Diego, California 92093, USA

³ Department of Medicine, University of California San Diego, California 92093, USA

Conflicts of Interest and Source of Funding: The authors do not have a commercial or other association that might pose a conflict of interest. This research was supported by the National Institute of Mental Health [grant number R01 MH099987, P30 MH062512], the National Institute on Drug Abuse [grant number T32 DA031098 (stipend support to NSS)], and the National Institute on Alcohol Abuse and Alcoholism [grant number F31 AA027198 (stipend support to EWP)].

Corresponding Author: David J. Moore, Ph.D., Professor of Psychiatry, University of California, San Diego, HIV Neurobehavioral Research Program, 220 Dickinson St, Suite B, MC8231, San Diego, CA 92103-8231, Phone: 619-543-5093, Fax: 619-543-1235, djmoore@ucsd.edu

This research has not been previously presented.

Running title: Frailty and CD4 increase risk for HAND

Abstract

Background: Frailty disproportionately affects people with HIV (PWH) and increased frailty in this already vulnerable population is associated with worse neurocognitive functioning. Whether frailty interacts with current and modifiable markers of HIV disease severity to synergistically increase risk for HIV-Associated Neurocognitive Disorders (HAND), however, is unknown and important for informing the clinical care of aging PWH.

Setting: UC San Diego's HIV Neurobehavioral Research Program

Methods: Participants were 178 people with HIV (PWH) evaluated between 2014 and 2019.

HIV disease severity was measured by current CD4 count and plasma HIV RNA. HAND diagnoses were made according to the Frascati criteria using a seven-domain neuropsychological battery and the Fried Phenotype criteria was used to assess frailty syndrome (0 to 5 symptoms). The independent and interactive effects of frailty and current HIV disease severity (i.e., CD4 count and plasma HIV RNA) on HAND were examined using multiple logistic regression.

Results: There was an interaction between CD4 count and frailty on HAND. Simple slopes showed that CD4 count and the likelihood of HAND were negatively associated at >1.25 symptoms of frailty, and conversely, that frailty and HAND were negatively associated at 642 or less cells/mm³. There was no significant independent or interactive effects of plasma HIV RNA and frailty on the likelihood of HAND.

Conclusions: In addition to monitoring CD4 count, assessing for frailty may be critical in older adults with HIV to potentially mitigate poor neurobehavioral outcomes. Longitudinal follow-up studies are needed to determine the directionality of these findings.

Key words: aging, frailty, CD4, viral load, AIDS, neuropsychology, cognition

INTRODUCTION

As of 2018, almost 50% of people with HIV (PWH) in the United States were aged 50 years or older ¹. Although incredible advancements in antiretroviral treatment have allowed PWH to achieve lifespans comparable to those without HIV, PWH are still more likely to have decreased healthspan ^{2,3}. For example, older PWH are more likely to acquire age-related comorbidities at younger ages, and have more non-HIV conditions, polypharmacy, and greater overall disease burden than their seronegative counterparts ⁴⁻⁶. HIV-associated neurocognitive disorders (HAND) are also highly prevalent among PWH, and are associated with multifactorial detriments to quality of life ⁷.

PWH also have higher rates of frailty and at younger ages, which further increases vulnerability to poor health-related outcomes ⁸⁻¹². In fact, greater frailty appears to be linearly associated with worse neurocognitive functioning among PWH ¹³. Whether frailty confers even greater risk for HAND in the presence of other risk factors, however, is unknown. For example, among individuals with Alzheimer's disease, frailty has been shown to moderate the relationship between neuropathological disease burden and clinical manifestation of dementia ¹⁴. Among PWH, examining a possible interaction between frailty and HIV disease severity on HAND is important for informing the clinical care of aging PWH, as these are modifiable risk factors that, if intervened upon, could improve quality of life and prolong healthspan.

Thus, the current study examined the interaction between frailty and markers of current HIV disease severity on likelihood of HAND. We hypothesized that worse HIV disease severity (i.e., low CD4 and/or high HIV RNAviral load) would be associated with greater risk of HAND only at higher levels of frailty, and vice versa. Importantly, our aims and hypotheses are only concerned with markers of *current* disease severity (i.e., CD4 cell count and HIV RNAviral

load) because they are intervenable. Notably, we did not examine ART use as a predictor because our sample consisted of very few individuals who were off ART (n=5). Although low nadir CD4 has been previously established as a predictor of HAND¹⁵, this measure is not intervenable/modifiable. Additionally, we examined frailty symptoms in a continuous fashion, as pre-frailty (1-2 symptoms) has been shown to predict poor health outcomes among PWH; thus, considering the full range of symptoms may be more sensitive in detecting a cumulative effect of frailty on HAND. In sum, examination of the independent and interactive effects of important modifiable risk factors (e.g., frailty and HIV disease severity) on risk of HAND is needed to further elucidate possible mechanisms for the development of HAND and inform multimodal comprehensive clinical interventions.

METHODS

Participants

Participants were 178 PWH (n=84 no HAND; n=94 HAND) enrolled in NIH-funded research studies at the UC San Diego's HIV Neurobehavioral Research Program (HNRP) from 2014 to 2019. Exclusion criteria were: 1) presence of a neurological condition known to impact neurocognitive functioning (e.g., non-HIV neurological disorder such as Parkinson's Disease or stroke); 2) history of head injury with loss of consciousness for longer than 30 minutes, seizure disorder, or central nervous system neoplasm; 3) diagnosis of a psychotic disorder or severe learning disorder (e.g., WRAT-4 Reading score <70); and 4) positive urine toxicology for illicit substances (excluding marijuana) on the day of testing. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (UCSD Human Research Protections Program

IRB00000355) and with the Helsinki Declaration of 1975 and its later amendments or comparable ethical standards.

HAND classification

All participants completed a comprehensive neurocognitive assessment that evaluated seven domains consistent with large-scale studies of HAND¹⁶. Raw neurocognitive test scores were converted to T-scores that adjusted for demographics based on established normative standards (age, education, sex, and race/ethnicity where available). Participants also completed a modified version of an Activities of Daily Living self-report questionnaire (Lawton & Brody, 1969), and were classified as having a functional deficit if they reported decreased ability to independently perform 2 or more instrumental activities of daily (e.g., managing finances, cooking). HAND diagnoses were made using Frascati criteria¹⁷, which require cognitive impairment (>1 SD below the mean) in at least two neurocognitive domains. HAND classification includes three subtypes, which in order of most severe to least severe are: HIV-associated dementia (HAD, $n=5$, 5%), mild neurocognitive disorder (MND, $n=21$, 22%), and asymptomatic neurocognitive impairment (ANI, $n=68$, 72%). Due to small numbers of individuals in some of the diagnostic levels, HAND diagnoses were evaluated dichotomously (HAND vs. no HAND).

Frailty Assessment

Frailty was assessed using the Fried Frailty Index¹⁸, which consists of five domains of physical functioning: 1) unintentional weight loss (self-reported ≥ 10 pounds lost in the past year); 2) weakness ($<20^{\text{th}}$ percentile of normative sample for grip strength, stratified by sex and

body mass index); 3) exhaustion (self-reported via elevations on items 7 and 9 of the Center for Epidemiologic Studies – Depression [CES-D] scale); 4) slow walking speed (<20th percentile of normative sample for total seconds to walk 15 feet, stratified by sex and height); and 5) low physical activity (<383 kcal/week for men, <270 kcal/week for women; self-reported via the International Physical Activity Questionnaire). Frailty was examined as a count of the presence of deficits in each of the five domains.

Psychiatric and Neuromedical Assessment

The Beck Depression Inventory, Second Edition (BDI-II) was used to assess current depressive symptoms. The WHO Composite International Diagnostic Interview (CIDI) was administered to diagnose participants for current and lifetime Major Depressive Disorder (MDD), as defined by the Fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV).

Neuromedical Assessment

All participants underwent a standardized medical history interview, neuromedical examination, and blood and urine collection. HIV serological status was confirmed via ELISA and Western blot test, and HIV RNA levels were measured in plasma by rtPCR (Amplicor, Roche Diagnostics, Indianapolis, IN; lower limit of quantitation [LLQ] of 50 copies/ml). Current CD4 were measured in plasma using flow cytometry. Self-reported HIV disease and treatment variables included nadir CD4, AIDS status, estimated duration of HIV disease, and current ART regimen. Comorbid medical conditions (i.e., hepatitis C, diabetes, hypertensionhypertension, and hyperlipidemia) were determined by self-report and/or medical chart review when available.

Statistical Analyses

Demographics, psychiatric and neuromedical characteristics, and frailty symptoms were compared by HAND status using paired independent t-test, Wilcoxon test, or Chi-Square test as appropriate. Nominal logistic regressions were conducted to examine the odds of having a HAND diagnosis as a function of number of frailty symptoms, markers of current HIV disease severity (CD4 and plasma HIV RNA viral load), and their interaction. Covariates were chosen based on the pattern of univariable differences by HAND status. These included age, premorbid verbal IQ estimate, hypertension, hyperlipidemia, and diabetes. Pairwise and regression analyses were performed using JMP Pro version 14.0.0 (JMP, Version <14.0.0>. SAS Institute Inc., Cary, NC, 1989-2007). The CAHOST Microsoft Excel 2013 workbook was used to determine regions of moderation significance using the Johnson-Neyman procedure¹⁹.

RESULTS

Participant characteristics are displayed in Table 1. HAND subtypes included 5% HAD (n=5), 22% MND (n=21), and 72% ANI (n=68). Participants with HAND were older ($p=0.01$) and had lower estimated premorbid verbal IQs ($p<0.001$) than those without HAND. HAND groups were comparable on all other demographic, psychiatric, and HIV disease characteristics ($ps>0.10$). HAND groups did not differ on Fried frailty status or the average number of Fried frailty symptoms, however participants with HAND were more likely to meet criteria for slow walking speed compared to those without HAND ($p=0.001$). Participants with HAND also had higher rates of diabetes ($p=0.04$), hypertension ($p<0.001$), and hyperlipidemia ($p=0.04$) compared to those without HAND.

A logistic regression model was used to examine the independent and interactive effects of plasma CD4 count and number of frailty symptoms on the likelihood of a HAND diagnosis, covarying for factors that differed between HAND groups (i.e., age, estimated premorbid verbal IQ, hypertension, hyperlipidemia, and diabetes). The interaction between CD4 and number of frailty symptoms was significant ($b=-0.001$, $SE=0.001$, $p=0.037$). Independent main effects of CD4 ($b=-0.0004$, $SE=0.0006$, $p=0.510$) and number of frailty symptoms ($b=0.014$, $SE=0.190$, $p=0.942$) were not significant. Higher estimated premorbid verbal IQ significantly related to lower likelihood of HAND ($b=-0.047$, $SE=0.013$, $p=0.001$), but the other covariates did not significantly explain the variance in the likelihood of HAND (age: $b=0.037$, $SE=0.19$, $p=0.050$; hypertension: $b=0.315$, $SE=0.196$, $p=0.107$; hyperlipidemia: $b=-0.040$, $SE=0.200$, $p=0.843$; diabetes: $b=0.131$, $SE=0.252$, $p=0.603$).

The critical level in which the interaction between CD4 and number of frailty symptoms was significant was probed using the Johnson-Neyman technique. When examining frailty as the moderator, results revealed that the negative relationship between CD4 and likelihood of HAND was significant only among participants with frailty greater than 1.25 symptoms (Figure 1A). That is, among participants with more than 1.25 frailty symptoms, lower CD4 related to higher likelihood of HAND. For clinical interpretability, Figure 1B illustrates simple slopes of the interaction effect at higher (2 or more symptoms) and lower levels of frailty (0 or 1 symptoms). When examining CD4 as the moderator, results showed that the positive relationship between frailty symptoms and the likelihood of HAND was significant only among participants with less than or equal to 642 CD4 cells/mm³ (Figure 1C). That is, among participants with ≤ 642 CD4 cells/mm³, a higher number of frailty symptoms related to higher likelihood of HAND (Figure 1D).

The next logistic regression revealed no significant independent or interactive effects of plasma HIV RNAviral load and number of frailty symptoms on the likelihood of HAND ($p>0.05$). Notably, the distribution of plasma HIV RNAviral load values was non-normal (right skewed) and restricted in range, as the majority participants were virally suppressed ($n=168$, 94% of entire sample). When we removed those who were virally unsuppressed ($n=21$), the moderation between CD4 and frailty still held ($b=-.002$, $SE=.001$, $p=.015$).

DISCUSSION

This study investigated the independent and interactive effects of current HIV disease severity (i.e., CD4 cell count, plasma HIV RNAviral load) and number of frailty symptoms on the likelihood of HAND. We found a significant interaction between CD4 and frailty on HAND. When frailty was examined as the moderating variable, the relationship between CD4 and HAND became significant at 1.25 or more symptoms (2 symptoms for clinical relevance), such that lower CD4 was associated with increased likelihood of having HAND. Inversely, when CD4 was examined as the moderator, the relationship between frailty and HAND became significant at 642 or less cells/mm³, such that higher number of frailty symptoms was associated with increased likelihood of HAND. Plasma HIV RNAviral load did not associate with HAND or interact with frailty.

Results highlight the importance of considering both frailty and CD4 in PWH at risk for neurocognitive impairment. We found that frailty is critical even at low levels. This is consistent with previous research showing that one to two symptoms of frailty (pre-frailty) is associated with neurocognitive impairments among community-dwelling adults²⁰, and is predictive of neurocognitive decline over two years among PWH²¹. Furthermore, rates of frailty and pre-

frailty in our sample were consistent with other samples of PWH²². Our results additionally suggest that frailty, in conjunction with low CD4, can be especially problematic for cognition to the extent of a diagnosable neurocognitive disorder. Interestingly and unexpectedly, CD4 was shown to be important even up to 642 cells/mm³, which is at a level traditionally accepted as within the normal range (500-1,500 cells/mm³). While nadir CD4 traditionally has been demonstrated to predict HAND¹⁵, this study uniquely establishes a relationship between current CD4 (interacting with frailty) and HAND, which has significant clinical implications because unlike nadir, current cell count is modifiable.

To our knowledge, this is the first study to investigate the interaction of frailty and markers of current HIV disease severity on HAND. Several limitations of the present study should be noted to guide future studies. First, the sample consists of relatively healthy individuals with few having plasma HIV RNA viral load less than 50 copies/ml. This restricted range decreases our confidence in concluding that HIV RNA viral load does not have the same interactive effect with frailty on HAND as CD4 at this time. CSF HIV RNA viral load was considered because its levels (at least as high as plasma HIV RNA levels viral load) have been shown to correlate with HAND²³. However, due to the small sample size of participants with CSF data (n=48), analyses on CSF values were not done at this time, but would be important to investigate in future studies. Another limitation is that the number of frailty symptoms in our sample only ranged from 0-4 (5 possible), which may have impacted the magnitude of the its interactive effect with CD4. Lastly, our sample consisted of few females (12%), which limits our ability to generalize our findings to these individuals.

In summary, our findings support an interaction between frailty and CD4 on the likelihood of HAND. Clinically, providers may be impactful in mitigating HAND by screening for frailty in the context of relatively lower CD4 counts, or more closely follow CD4 counts in the context of 2 or more symptoms of frailty. A CD4 count below 642 cells mm³ should prompt clinicians to assess for frailty, and identification of 2 frailty symptoms in PWH should prompt for closer monitoring of CD4 to identify or possibility mitigate neurocognitive impairment. Future studies examining the moderating effect of frailty on neurodegeneration and HAND would be an important next step to further investigate the role of frailty on HIV disease and cognition.

ACKNOWLEDGEMENTS

The HIV Neurobehavioral Research Center (HNRC) is supported by Center award P30MH062512 from NIMH.

* The San Diego HIV Neurobehavioral Research Center [HNRC] group is affiliated with the University of California, San Diego, the Naval Hospital, San Diego, and the Veterans Affairs San Diego Healthcare System, and includes: Director: Robert K. Heaton, Ph.D., Co-Director: Igor Grant, M.D.; Associate Directors: J. Hampton Atkinson, M.D., Ronald J. Ellis, M.D., Ph.D., and Scott Letendre, M.D.; Center Manager: Jennifer Iudicello, Ph.D.; Donald Franklin, Jr.; Melanie Sherman; NeuroAssessment Core: Ronald J. Ellis, M.D., Ph.D. (P.I.), Scott Letendre, M.D., Thomas D. Marcotte, Ph.D, Christine Fennema-Notestine, Ph.D., Debra Rosario, M.P.H., Matthew Dawson; NeuroBiology Core: Cristian Achim, M.D., Ph.D. (P.I.), Ana Sanchez, Ph.D., Adam Fields, Ph.D.; NeuroGerm Core: Sara Gianella Weibel, M.D. (P.I.), David M. Smith, M.D., Rob Knight, Ph.D., Scott Peterson, Ph.D.; Developmental Core: Scott Letendre, M.D. (P.I.), J. Allen McCutchan; Participant Accrual and Retention Unit: J. Hampton Atkinson, M.D.

(P.I.) Susan Little, M.D., Jennifer Marquie-Beck, M.P.H.; Data Management and Information Systems Unit: Lucila Ohno-Machado, Ph.D. (P.I.), Clint Cushman; Statistics Unit: Ian Abramson, Ph.D. (P.I.), Florin Vaida, Ph.D. (Co-PI), Anya Umlauf, M.S., Bin Tang, M.S.

The views expressed in this article are those of the authors and do not reflect the official policy or position of the Department of the Navy, Department of Defense, nor the United States Government.

REFERENCES

1. Centers for Disease Control and Prevention. *HIV Surveillance Report, 2018*. 2019.
2. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. *Annu Rev Med*. 2011;62:141-155.
3. Moore RC, Fazeli PL, Jeste DV, et al. Successful cognitive aging and health-related quality of life in younger and older adults infected with HIV. *AIDS Behav*. 2014;18(6):1186-1197.
4. Kong AM, Pozen A, Anastos K, Kelvin EA, Nash D. Non-HIV Comorbid Conditions and Polypharmacy Among People Living with HIV Age 65 or Older Compared with HIV-Negative Individuals Age 65 or Older in the United States: A Retrospective Claims-Based Analysis. *AIDS patient care and STDs*. 2019;33(3):93-103.
5. Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2011;53(11):1120-1126.

6. Rodriguez-Penney AT, Iudicello JE, Riggs PK, et al. Co-morbidities in persons infected with HIV: increased burden with older age and negative effects on health-related quality of life. *AIDS patient care and STDs*. 2013;27(1):5-16.
7. Jones JD, Kuhn T, Levine A, et al. Changes in cognition precede changes in HRQoL among HIV+ males: Longitudinal analysis of the multicenter AIDS cohort study. *Neuropsychology*. 2019;33(3):370-378.
8. Desquilbet L, Jacobson LP, Fried LP, et al. HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. *J Gerontol A Biol Sci Med Sci*. 2007;62(11):1279-1286.
9. Erlandson KM, Schrack JA, Jankowski CM, Brown TT, Campbell TB. Functional impairment, disability, and frailty in adults aging with HIV-infection. *Curr HIV/AIDS Rep*. 2014;11(3):279-290.
10. Levett TJ, Cresswell FV, Malik MA, Fisher M, Wright J. Systematic Review of Prevalence and Predictors of Frailty in Individuals with Human Immunodeficiency Virus. *J Am Geriatr Soc*. 2016;64(5):1006-1014.
11. Rubtsova AA, Sabbag S, Sundermann E, et al. Frailty and Neurocognitive Impairment: Impacts on Quality of Life in HIV. *J Assoc Nurses AIDS Care*. 2019.
12. Piggott DA, Erlandson KM, Yarasheski KE. Frailty in HIV: Epidemiology, Biology, Measurement, Interventions, and Research Needs. *Curr HIV/AIDS Rep*. 2016;13(6):340-348.
13. Oppenheim H, Paolillo EW, Moore RC, et al. Neurocognitive functioning predicts frailty index in HIV. *Neurology*. 2018;91(2):e162-e170.

14. Wallace LMK, Theou O, Godin J, Andrew MK, Bennett DA, Rockwood K. Investigation of frailty as a moderator of the relationship between neuropathology and dementia in Alzheimer's disease: a cross-sectional analysis of data from the Rush Memory and Aging Project. *Lancet Neurol.* 2019;18(2):177-184.
15. Ellis RJ, Badiee J, Vaida F, et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. *AIDS.* 2011;25(14):1747-1751.
16. Heaton RK, Clifford DB, Franklin DR, Jr., et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. *Neurology.* 2010;75(23):2087-2096.
17. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. *Neurology.* 2007;69(18):1789-1799.
18. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci.* 2001;56(3):M146-156.
19. Carden SW, Holtzman NS, Strube MJ. CAHOST: An Excel Workbook for Facilitating the Johnson-Neyman Technique for Two-Way Interactions in Multiple Regression. *Front Psychol.* 2017;8:1293.
20. Robertson DA, Savva GM, Coen RF, Kenny RA. Cognitive function in the prefrailty and frailty syndrome. *J Am Geriatr Soc.* 2014;62(11):2118-2124.
21. Paolillo EW, Sun-Suslow N, Pasipanodya EC, et al. Pre-frailty predicts cognitive decline at 2-year follow-up in persons living with HIV. *J Neurovirol.* 2019:1-13.
22. Önen N, Patel P, Baker J, et al. Frailty and pre-frailty in a contemporary cohort of HIV-infected adults. *The Journal of frailty & aging.* 2014;3(3):158.

23. Letendre S. Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. *Top Antivir Med.* 2011;19(4):137-142.

FIGURE 1

(A) Using the Johnson-Neyman technique, the simple slope of CD4 count is only significant above 1.25 symptoms of frailty, such that the lower CD4 count relates to higher likelihood of HAND among participants with >1.25 frailty symptoms. (B) The negative relationship between CD4 count and likelihood of HAND among participants with 2-5 frailty symptoms is depicted by the solid line. In contrast, CD4 count is not significantly related to likelihood of HAND among participants with 0-1 frailty symptoms, as depicted by the dashed line. (C) Using the Johnson-Neyman technique, the simple slope of frailty is only significant at or below a CD4 count of 642, such that higher frailty relates to higher likelihood of HAND among participants with ≤ 642 CD4 cells. (D) The positive relationship between frailty symptoms and likelihood of HAND among participants with ≤ 642 CD4 cells is depicted by the dashed line. In contrast, frailty symptoms are not significantly related to likelihood of HAND among participants with >642 CD4 cells, as depicted by the solid line.

TABLE 1


Participant demographic and clinical characteristics by HAND diagnosis (N=178)

	No HAND (N=84)	HAND (N=94)	<i>p</i> -value
<i>Demographics</i>			
Age	52.15 (11.15)	56.21 (10.63)	.01
Sex (female)	14 (17%)	8 (9%)	.10
Education (years)	14.33 (2.48)	14.24 (2.68)	.47
Race/Ethnicity (Non-Hispanic White)	34 (40%)	44 (47%)	.40
Premorbid verbal IQ estimate ^a	107.20 (14.41)	99.27 (12.69)	<.001
Unemployed	51 (57%)	67 (70%)	.08
<i>Psychiatric Characteristics</i>			
BDI-II Score	8.24 (8.73)	8.68 (.99)	.39
Current MDD (yes)	8 (10%)	5 (6%)	.26
Lifetime MDD (yes)	47 (56%)	59 (63%)	.31
<i>HIV Disease Characteristics</i>			
History of AIDS (yes)	46 (55%)	62 (66%)	.10
Log ₁₀ Plasma HIV RNA viral load	1.29 (.66)	1.13 (.68)	.26
Plasma HIV RNA viral load detectability ^b	4 (5%)	6 (6%)	.74
Current CD4 count	641 [508, 863]	576 [421, 809]	.26
Nadir CD4 count	197 [53, 352]	174 [30, 303]	.29
Estimated years living with HIV	18.59 (9.11)	19.56 (9.15)	.46

On ART (yes)	82 (98%)	91 (97%)	.92
<i>Fried Frailty</i>			
Average number of frailty symptoms	1.16 (1.14)	1.04 (.98)	.79
Frailty	5 (6)	10 (11)	.26
Prefrailty	38 (46)	43 (46)	.99
Weight loss (yes)	11 (13%)	14 (15%)	.73
Weakness (yes)	11 (13%)	13 (14%)	.89
Exhaustion (yes)	31 (37%)	26 (28%)	.19
Slow walking speed (yes)	3 (4%)	18 (19%)	.001
Low physical activity (yes)	17 (20%)	26 (28%)	.25
<i>Comorbid Health Conditions</i>			
Hepatitis C (yes)	21 (26%)	17 (18%)	.22
Diabetes (yes)	9 (11%)	21 (23%)	.04
Hypertension (yes)	31 (38%)	59 (64%)	<.001
Hyperlipidemia (yes)	34 (42%)	53 (58%)	.04

Note. All values presented as mean (SD), median [IQR], or n (%); groups were compared using paired independent t-test, Wilcoxon test, or Chi-Square test as appropriate; ^aWRAT-4=Wide Range Achievement Test-Fourth Edition; ^b≤50 copies/mL; BDI-II=Beck Depression Inventory-Second Edition; MDD=Major Depressive Disorder; ART=antiretroviral therapy

FIGURE 1



(A) Using the Johnson-Neyman technique, the simple slope of CD4 count is only significant above 1.25 symptoms of frailty, such that the lower CD4 count relates to higher likelihood of HAND among participants with >1.25 frailty symptoms. (B) The negative relationship between CD4 count and likelihood of HAND among participants with 2-5 frailty symptoms is depicted by the solid line. In contrast, CD4 count is not significantly related to likelihood of HAND among participants with 0-1 frailty symptoms, as depicted by the dashed line. (C) Using the Johnson-Neyman technique, the simple slope of frailty is only significant at or below a CD4 count of 642, such that higher frailty relates to higher likelihood of HAND among participants with ≤642 CD4 cells. (D) The positive relationship between frailty symptoms and likelihood of HAND among participants with ≤642 CD4 cells is depicted by the dashed line. In contrast, frailty symptoms are not significantly related to likelihood of HAND among participants with >642 CD4 cells, as depicted by the solid line.